Rice, Lawrence

Publications

Sort by

Co-Author Network

selected publications

The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia. Journal of thrombosis and haemostasis : JTH. 2019 Academic Article GET IT
Times cited: 40
Acquired and Hereditary Hypercoagulable States in Patients with Continuous Flow Left Ventricular Assist Devices: Prevalence and Thrombotic Complications. Journal of cardiac failure. 2016 Academic Article GET IT
Times cited: 12
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Information Resource GET IT
Times cited: 55
There Is No Such Thing as a "Positive" Antibody Test: Diagnosing Heparin-Induced Thrombocytopenia in 2015. Chest. 2015 Editorial Article GET IT
Times cited: 10
Sickle cell patients face death in the ICU*. Critical care medicine. 2014 Editorial Article GET IT
Times cited: 1
Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide. Clinical lymphoma, myeloma & leukemia. 2013 Academic Article GET IT
Times cited: 10
Amyloidosis: changing approaches and outcomes. Methodist DeBakey cardiovascular journal. 2012 Academic Article GET IT
Times cited: 1
PF4/heparin antibody testing and treatment of heparin-induced thrombocytopenia in the intensive care unit. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2012 Academic Article GET IT
Times cited: 8
A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study. American journal of therapeutics. 2011 Academic Article GET IT
Times cited: 32
The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. Journal of thrombosis and haemostasis : JTH. 2010 Academic Article GET IT
Times cited: 181
Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. Clinical therapeutics. 2010 Academic Article GET IT
Times cited: 13
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leukemia research. 2009 Academic Article GET IT
Times cited: 38
Treatment of immune thrombocytopenic purpura: focus on eltrombopag. Biologics : targets & therapy. 2009 Academic Article GET IT
Changes of red blood cell surface markers in a blood doping model of neocytolysis. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2009 Academic Article GET IT
Times cited: 16
Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study. Pathology, research and practice. 2009 Academic Article GET IT
Times cited: 8
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. American heart journal. 2009 Academic Article GET IT
Times cited: 39
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. British journal of haematology. 2008 Academic Article GET IT
Times cited: 112
p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes. American journal of clinical pathology. 2008 Academic Article GET IT
Times cited: 12
The implication of identifying JAK2 ( V617F ) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis. Journal of hematopathology. 2008 Academic Article GET IT
Times cited: 12
The role of beta-catenin in chronic myeloproliferative disorders. Human pathology. 2008 Academic Article GET IT
Times cited: 6
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (London, England). 2008 Academic Article GET IT
Times cited: 639
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Archives of internal medicine. 2008 Academic Article GET IT
Times cited: 85
P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. British journal of haematology. 2008 Academic Article GET IT
Times cited: 44
Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Archives of pathology & laboratory medicine. 2007 Academic Article GET IT
Times cited: 23
Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. Journal of clinical pharmacology. 2007 Academic Article GET IT
Times cited: 26
Drug evaluation: AMG-531 for the treatment of thrombocytopenias. Current opinion in investigational drugs (London, England : 2000). 2006 Information Resource GET IT
Times cited: 14
Current management of the myeloproliferative disorders: a case-based review. Archives of pathology & laboratory medicine. 2006 Information Resource GET IT
Times cited: 13
Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. Journal of intensive care medicine. 2006 Academic Article GET IT
Times cited: 30
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 75
Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. Journal of thrombosis and thrombolysis. 2005 Academic Article GET IT
Times cited: 31
The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2005 Information Resource GET IT
Times cited: 137
Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface. Current pharmaceutical design. 2004 Information Resource GET IT
Times cited: 39
Preventing complications in heparin-induced thrombocytopenia. Alternative anticoagulants are improving patient outcomes. Postgraduate medicine. 2002 Academic Article GET IT
Erythropoietin withdrawal alters interactions between young red blood cells, splenic endothelial cells, and macrophages: an in vitro model of neocytolysis. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2001 Academic Article GET IT
Times cited: 35
Neocytolysis on descent from altitude: a newly recognized mechanism for the control of red cell mass. Annals of internal medicine. 2001 Academic Article GET IT
Times cited: 110
Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Annals of internal medicine. 2000 Academic Article GET IT
Times cited: 210
Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. American journal of hematology. 1998 Academic Article GET IT
Times cited: 89
Efficacy of danazol with autoimmune thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis. 1997 Article
Splenectomy for relapsing thrombotic thrombocytopenic purpura. Annals of internal medicine. 1997 Article GET IT
Assessment of tissue iron overload by nuclear magnetic resonance imaging. The American journal of medicine. 1989 Academic Article GET IT
Times cited: 102
Ringed sideroblasts in primary myelodysplasia. Leukemic propensity and prognostic factors. Archives of internal medicine. 1988 Academic Article GET IT
Times cited: 4
Suppression of lymphocyte responses by monocytes with untreated and treated multiple myeloma. Blood. 1982 Academic Article GET IT
Times cited: 10
Suppression of lymphocyte responses by monocytoid cells does not require cell-cell contact. Cellular immunology. 1981 Academic Article GET IT
Times cited: 7
Serum haptoglobin in hemolytic disease. JAMA. 1980 Article GET IT
Times cited: 2
Spectrum of immunodeficiencies with Hodgkin's disease. The Journal of clinical investigation. 1980 Academic Article GET IT
Times cited: 40
Development of circulating platelet aggregates during heparin therapy. Clinical Research. 1979 Article
Three suppressor systems in human blood that modulate lymphoproliferation. Journal of immunology (Baltimore, Md. : 1950). 1979 Academic Article GET IT
Times cited: 83

more ...

less ...

Background

education and training

M.D., Emory University School of Medicine 1974
B.S., University of Florida 1970

Contact

full name

Lawrence Rice

primary email

lrice@tmhs.org

VIVO Weill Cornell Medical College

Lawrence Rice Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email